Immunotherapy: A new paradigm shift in the treatment of advanced NSCLC

Speaker: Marina Garassino

In an ESMO expert interview, M. Garassino discusses the practice changing data presented at 2015 ASCO Annual Meeting with PD-1 blockade across NSCLC histologies. In particular, she elaborates data from the CheckMate 017 in squamous cell NSCLC and a twin CheckMate 057 study in non-squamous cell NSCLC; the toxicities of nivolumab were reversible and better than with docetaxel, the current standard of care. In addition she discusses the other immunotherapy data, an emerging and rapidly evolved field of research in the NSCLC treatment.

Discussion Points

  • Advanced non-squamous NSCLC: nivolumab vs docetaxel in CheckMate 057
  • Anti-PD-L1: New findings in a phase II study
  • Preliminary data from KEYNOTE-021 cohort D are promising
  • A new paradigm for the treatment of NSCLC